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Abstract
Transthoracic echocardiography is a primary non-invasive modality for investigation of heart
transplant recipients. It is a versatile tool which provides comprehensive information about cardiac
structure and function. Echocardiographic examinations can be easily performed at the bedside and
serially repeated without any patient's discomfort. This review highlights the usefulness of Doppler
echocardiography in the assessment of left ventricular and right ventricular systolic and diastolic
function, of left ventricular mass, valvular heart disease, pulmonary arterial hypertension and
pericardial effusion in heart transplant recipients. The main experiences performed by either
standard Doppler echocardiography and new high-tech ultrasound technologies are summarised,
pointing out advantages and limitations of the described techniques in diagnosing acute allograft
rejection and cardiac graft vasculopathy. Despite the sustained efforts of echocardiographic
technique in predicting the biopsy state, endocardial myocardial biopsies are still regarded as the
gold standard for detection of acute allograft rejection. Conversely, stress echocardiography is able
to identify accurately cardiac graft vasculopathy and has a recognised prognostic in this clinical
setting. A normal stress-echo justifies postponement of invasive studies. Another use of
transthoracic echocardiography is the monitorisation and the visualisation of the catheter during
the performance of endomyocardial biopsy. Bedside stress echocardiography is even useful to
select appropriately heart donors with brain death. The ultrasound monitoring is simple and
effective for monitoring a safe performance of biopsy procedures.
Background
Over the past decade heart transplantation (HT) has
evolved from a rarely performed procedure to an accepted
therapy for advanced heart failure. About 45% of the can-
didates to HT have ischemic cardiomyopathy while 55%
have some form of dilated cardiomyopathy of various ori-
gin. The prognosis for HT patients following the ortho-
topic procedure has greatly improved over the past 20
years, and a recent report (August 2006) of Heart Trans-
plants: Statistics of American Heart Association. informs
that the 5 years survival rates is 66.9% in women and
71.2% in men. Although significant advances have been
reached in surgical techniques, in donor and recipient
selection criteria, and also in the management of trans-
plant patients, allograft rejection remains the most impor-
tant cause of morbidity and. the primary limitation for the
survival of these patients.
Acute allograft rejection (AAR) is frequent in the first
months after HT. Because it is initially asymptomatic, reg-
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ular rejection surveillance is obligatory by monitoring
immunosuppressive treatment, clinical and laboratory
data and, in particular, by performing endomyocardial
biopsies (EMBs), which represent the gold standard for
the detection of rejection. AAR is characterised histologi-
cally by inflammatory cell infiltrates, interstitial edema
and myocite necrosis which ultimately translates into
structural and functional abnormalities of the allograft. A
first international grading system for cardiac allograft
biopsies, adopted in 1990 by the International Society for
Heart Transplantation [1], has been updated in 2004 by
the International Society for Heart and Lung Transplanta-
tion (ISHLT) (Table 1) [2].
Long-term survival of allografted hearts is limited by a
progressive fibro-proliferative disease, resulting in intimal
thickening and occlusion of the grafted coronary vessels.
This disease, variously defined as accelerated transplant
coronary artery disease (CAD) or cardiac graft vasculopa-
thy (CAV), is also known as chronic allograft rejection
[3]). After the first year transplant peripheral and cerebro-
vascular disease, end-stage renal disease, malignancy and
infections are the other main causes of death. Specific
side-effects of the immunosuppressive agents like renal
failure, arterial hypertension and diabetes mellitus shall
be also taken into account.
The role of Doppler echocardiography in the transplanted 
heart
Echocardiography is particularly useful for the assessment
of HT recipients since it is easily performable and not
associated with the risks of the invasive procedures. Its
versatility allows it to be applied in a wide variety of situ-
ations in the post-transplant setting.
The echocardiographic features of left and right atria
During HT procedure donor cardiectomy involves only
partial atrial resection. With the standard surgical proce-
dure (biatrial surgical approach) an anastomosis is made
between the residual recipient atrial tissue and the donor
atria such that there is a characteristic unique echocardio-
graphic atrial morphological appearance. Therefore,
transplanted hearts have increased size in both atria, pri-
marily caused by an increase in their long-axis dimension.
Sometimes, an echo dense ridge is also visualisable at
mid-atrial level (best appreciated in apical 4-chamber
view), it being the site of anastomosis between the resid-
ual recipient atrial tissue and the donor atria [4] (Figure
1). The standard surgical technique has been reported to
contribute to sub-optimal hemodynamics, specifically
abnormal patterns of LV filling and to predispose to atrial
thrombus formation, due to blood stasis in the dilated
atrial cavities [5]. It is not unexpected, therefore, that post-
HT echocardiographically determined left atrial area is
inversely correlated with patient's survival [4]. The bicaval
operative technique, introduced in the last decade, is associ-
ated with better preservation of atrial morphology [6] and
lower risk for development of atrial thrombus [7].
Assessment of left ventricular systolic function
The normalisation of left ventricular (LV) systolic func-
tion (M-mode derived endocardial fractional shortening
or 2-D ejection fraction [EF])) after successful HT is
responsible for early improvement of symptoms and has
a strong impact on prognosis. In AAR LV systolic function
is rarely affected but an early alteration of fractional short-
ening predicts subsequent development of CAV [8]. On a
cohort of 65 HT recipients, 10–15 years after surgery, LV
chamber dimension were well maintained and mean EF
was 63% [9]. LV systolic dysfunction late after HT is often
due to the effects of CAV and is associated to a poor prog-
nosis [10]. Worthy of note, pulsed Tissue Doppler derived
myocardial systolic velocity (Sm) of ≤ 10 cm/s has been
found to be associated with a 97.2% likelihood for trans-
plant CAD whereas Sm values of > 11 cm/s exclude CAD
with 90.2% probability [11].
Assessment of left ventricular diastolic function
Although early AAR can be often responsible for the devel-
opment of LV restrictive pattern, the recent literature does
not support the use of Doppler indices of LV diastolic
function as markers of AAR [12]. Standard Doppler
appears as a method with an excellent specificity but
insufficient sensitivity and this is mainly due to the influ-
ence of recipient atrial contraction timing on early ven-
tricular filling and to sinus tachycardia which induces a
frequent overlapping between E and A velocities [13]. Pre-
serving left atrial morphology by using surgical bicaval
techniques permits the maintenance of normal ventricu-
lar filling dynamics [4]. Because of the relatively load
independency of myocardial velocities demonstrated also
in HT recipients [14], pulsed Tissue Doppler has been pro-
Table 1: Grading of rejection of endomyocardial biopsy according to International Society of Heart and Lung Transplantation (update 
2004)
Grade Signs of rejection
Grade 0 R No acute cellular rejection
Grade 1 R Mild, low-grade, acute cellular rejection
Grade 2 R Moderate, intermediate-grade, acute cellular rejection
Grade 3 R Severe, high-grade, acute cellular rejectionCardiovascular Ultrasound 2008, 6:2 http://www.cardiovascularultrasound.com/content/6/1/2
Page 3 of 12
(page number not for citation purposes)
posed for the evaluation of LV diastolic properties due to
AAR [11,15,16]. In the experience of Dandel et al, the neg-
ative and positive predictive values for AAR and transplant
CAD of Tissue Doppler derived myocardial early diastolic
velocity (Em) appeared high enough (= 92–96%) to allow
a reliable non-invasive monitoring, instead of routinely
scheduled EMBs [11]. Another study, which used Am
velocity, has reported less favourable data, with good sen-
sitivity (= 82%) but low specificity (= 53%) in predicting
significant AAR [17]. In 50 HT patients, assessed by either
right-sided cardiac catheterisation and Doppler echocar-
diography (including pulsed Tissue Doppler of the mitral
annulus) simultaneously, mean wedge pressure was
related weakly to mitral inflow variables but strongly to E/
Em [r = 0.80; wedge pressure = 2.6+1.46(E/Em)] [18] (Fig-
ure 3), an index validated also in the general clinical set-
ting (19). Figure 2 shows a slightly abnormal E/Em ratio
(= 9) in a transplanted patient (normal cut-off value < 8)
[19].
Index of Myocardial Performance (IMP)
IMP is an index which combines LV systolic and diastolic
parameters (= (IVRT + ICT/LVET, where IVRT = isovolu-
mic relaxation time, ICT = Isovolumic contraction time
and LVET = left ventricular ejection time) and gives infor-
mation about LV global performance [20]. The rationale
for using IMP in this setting is that, during AAR, LV diasto-
lic dysfunction can be accompanied by subtle abnormali-
In the upper left panel a pericardial view (frontal) showing the edge of both atria which are preserved for conventional surgical  technique (Shumway technique): possibility of interatrial ridge are dependent of the redundancy of donor as well as recipient  residual tissue (arrows) Figure 1
In the upper left panel a pericardial view (frontal) showing the edge of both atria which are preserved for conventional surgical 
technique (Shumway technique): possibility of interatrial ridge are dependent of the redundancy of donor as well as recipient 
residual tissue (arrows). In the upper right panel pericardial view (frontal) showing how the edge of both atria are removed for 
bicaval surgical technique: possibility of interatrial ridge are dependent of the redundancy of recipient septal residual tissue only 
(arrow). In the lower panel 2-D echocardiographic apical 4-chamber view showing left atrial enlargement and point of suture of 
a transplanted heart. Mod from Heart Transplantation – Churcill Livingstone – James K. Kirklin et al. 2002.Cardiovascular Ultrasound 2008, 6:2 http://www.cardiovascularultrasound.com/content/6/1/2
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ties of LV systolic performance and these are potentially
reflected in changes of systolic time intervals. Accordingly,
IMP has demonstrated to be sensitive to initial alterations
of cardiac function in paediatric patients with AAR
[21,22]. In 20 HT adult recipients with grade 3A cellular
rejection, there was a mean increase of IMP by 98% (p <
0.0001) during the AAR episode and a decrease to its base-
line values after treatment; in addition, the change in IMP
was independent of both baseline EF and EF changes dur-
ing AAR [23]. IMP could be, therefore, an useful non-inva-
sive indicator, in order to assess the impact of therapy for
amelioration of AAR. However, in another experience
[24], the comparison of intra-recipient changes in Dop-
pler intervals between rejection and non-rejection states
demonstrated prolongation of IVRT and shortening of
ICT during AAR, with no change in the IMP. It is possible
that during AAR IVRT fall is counterbalanced by ICT pro-
longation and this may result in no significant change of
IMP.
Left ventricular mass
After HT, it is evident an increase in wall thickness and LV
mass, which can be detected and followed during time by
serial echocardiographic examinations. LV hypertrophy is
due to several causes (repetitive rejections, arterial hyper-
tension, immunosuppressive therapy, chronic tachycardia
and denervation) and its progression occurs mainly in
relation to cyclosporine levels and blood pressure levels
[25]. It is worthy of note that severe LV hypertrophy pre-
dicts mortality at 1-year follow-up in HT recipients [26].
Valvular heart disease
Valvular regurgitation is a fairly common occurrence
immediately post HT but structural abnormalities of the
aortic and mitral valves are not observed frequently after
HT. In a long-term follow-up study, only 13 of 65 patients
had mitral valve regurgitation (no patients had severe
regurgitation), three cases of aortic valve regurgitation
were reported and no patient has significant aortic valve
stenosis [10]. Possible causes of mitral regurgitation
include papillary muscle ischemia and the effect of multi-
ple AAR episodes.
Tricuspid valve regurgitation
In contrast to the left-sided valves, tricuspid valve regurgi-
tation is very common after HT, its etiology being multi-
Standard Doppler derived transmitral inflow pattern (left panel) and Pulsed Tissue Doppler of the lateral mitral annulus in a HT  recipient Figure 2
Standard Doppler derived transmitral inflow pattern (left panel) and Pulsed Tissue Doppler of the lateral mitral annulus in a HT 
recipient. The ratio is = .9.Cardiovascular Ultrasound 2008, 6:2 http://www.cardiovascularultrasound.com/content/6/1/2
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factorial. When its appearance is early after HT, probably
it is related to elevated pulmonary arterial pressures and
vascular resistance in the recipient as well as to atrial struc-
ture and function (in patients who had undergone stand-
ard biatrial surgical approach). In the majority of the
cases, the resolution of tricuspid regurgitation is possible
within 1 month after HT, hand in hand with the normal-
isation of pulmonary arterial pressures [27]. Tricuspid
regurgitation may be also due to injury of the chordal
apparatus caused by the repeated EMBs. Biopsy-induced
damage includes flail tricuspid leaflets and severe eccen-
tric jets of regurgitations. A direct correlation between
number of biopsies and severity of tricuspid regurgitation
has been demonstrated: a number <31 EMBs significantly
predicts a reduced risk of severe tricuspid regurgitation
[28]. Regardless of cause, the persistence of tricuspid
regurgitation is related to symptomatic right ventricular
(RV) failure, impaired renal function and increased mor-
tality [29].
The right ventricle
Because of the high prevalence of tricuspid valve regurgi-
tation the assessment of RV systolic function is necessary
in HT recipients. Although the majority of the cases of
early RV dilation and associated hemodynamic change
improve progressively in a matter of a week after HT [30],
RV failure is a recognised cause of in-hospital death and
some survivors have residual RV dilation. A relationship
In the upper panel relation (left) and plot of Bland-Altman (right) between pulmonary capillary wedge pressure (PCWP) and  mean mitral E/Ea ratio in transplant recipients Figure 3
In the upper panel relation (left) and plot of Bland-Altman (right) between pulmonary capillary wedge pressure (PCWP) and 
mean mitral E/Ea ratio in transplant recipients. In the lower panel relation (left) and plot of Bland-Altman (right) between inva-
sive mean right atrial pressure (RAP) and mean tricuspid E/Ea ratio in transplant recipients. (mod from Sudereswaran et al, Am 
J Cardiol 1998).Cardiovascular Ultrasound 2008, 6:2 http://www.cardiovascularultrasound.com/content/6/1/2
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between the evidence of RV dysfunction and plasma B-
type natriuretic peptide has also been observed [31]. In
addition, even when RV systolic function appears normal,
more subtle RV dysfunction can be unmasked by RV
pulsed Tissue Doppler. In paediatric HT recipients, Sm
velocity of the lateral tricuspid annulus has demonstrated
to be lower than in controls, showing a trend to a further
reduction during time [32]. In the experience of Suderas-
waran et al, similar to LV filling pressure, mean right atrial
pressure was related weakly to routine tricuspid inflow
variables but strongly to tricuspid E/Em [r = 0.79; n = 38;
right atrial pressure = 1.76(E/Em) - 3.7] after HT (18) (Fig-
ure 3). In addition, in 18 of these patients who repeated
right-sided cardiac catheterizations during time, the
changes in mean right atrial pressure were well detected
by Doppler, with a mean difference of 0 ± 3.45 mm Hg
(18). In this view, pulsed Tissue Doppler of the tricuspid
annulus should be recommended in the follow-up of
transplanted patients [33].
Pericardial effusion
Moderate to large pericardial effusions, due to a mismatch
between recipient and donor hearts or to the presence of
AAR or even to the effect of some immunosuppressive
drugs, occurs frequently during the early phase after HT.
However, the sensitivity (= 49%) and specificity (= 74%)
for diagnosis of AAR are limited [34] The possibility of an
infective cause for a pericardial effusion should always
been taken into account in these patients who are often
immuno-depressed. Close echocardiographic monitoring
is required in order to avoid heart tamponade. Pericardial
effusion is not associated, however, with any adverse clin-
ical outcomes and progressively disappears. If a large peri-
cardial effusion accumulates slowly it may be of a little
hemodynamic impact [35,36].
Potential role of high-technology ultrasound tools
Integrated backscatter (IBS) appears able to identify AAR
by the decrease of cyclic variation signal [37] and the
increase of 2-D derived end-diastolic IBS signal of either
posterior or septal wall [38]. The off-line analysis of col-
our Tissue Doppler and strain rate imaging (SRI), a tool
which quantifies myocardial wall deformation and distin-
guishes "true" active myocardial contraction from passive
wall motion [39], has been experimented in HT recipient.
"Healthy" HT patients may have normal global systolic
function but altered regional systolic deformation com-
pared to normal hearts [40]. SRI might be, therefore, an
additional tool for detecting = IB grade of AAR [41] and
reduce the number of EMBs. Despite promising, however,
high-tech ultrasound technologies have been applied only
on small number of HT recipients and their confirmation
in larger population samples is needed.
Acute allograft rejection
Several attempts have been performed during time to take
advantage by M-mode and 2-D echocardiography to diag-
nose AAR. The main echocardiographic variables pro-
posed for diagnosis of AAR include increased wall
thickness and wall echogenity, pericardial effusion, LV
diastolic dysfunction and regional/global LV systolic dys-
function [42]. Table 2 sumarises the sensitivity and specif-
icity of Doppler echocardiography in the main studies
performed [23,38,43-46]. In general, the results are not
encouraging and, when an echocardiographic parameter
appears appropriate, confirmatory results are lacking.
Although in the absence of key specific echo abnormali-
ties the probability of AAR is relatively low, no single
echocardiographic variable alone may be used for accu-
rate detection of AAR. Of interest, an experience of Picano
et al [47] showed that histologically verified rejection is
accompanied by normal global wall motion during stress-
induced ECG ST-segment depression. This recalls the well
known stress-echo response pattern of microvascular
angina, characterized by normal epicardial coronary arter-
ies and reduced coronary flow reserve (CFR), which can,
indeed, acutely and transiently reduced by AAR [48].
Despite these evidences, Doppler echocardiography is not
routinely used to diagnose AAR. It is expectable that the
effect of bicaval procedure on Doppler, the development
Table 2: Main studies evaluating the accuracy of standard Doppler echocardiography in detecting AAR
Authors N. of patients Method/Parameter Sensitivity Specificity
Desruennes M, J Am Coll Cardiol 1988 55 Standard Doppler, PHT decrease (20%) 88% 87%
Simmonds MB, Circulation 1992 30 Standard Doppler, superior vena caval SFFV ≤ 17 cm/s 100% 80%
Morocutti G, J Heart Lung Transplant 1995 18 Standard Doppler, PHT ≤ 55 ms
PHT ≤ 60 ms
69%
62%
76%
83%
Mouly-Bandini A, Transpl Int 1996 23 Standard Doppler, IVRT decrease ≥ 20% 45% -
Angermann GE, Circulation 1997 52 M-mode and 2D parameters 40–55% 84–87%
Stengel SM, Heart 2001 141 Pulsed Tissue Doppler. Am of mitral annulus < 8.7 cm/s 82% 53%
Vivekananthan K, Am J Cardiol 2002 20 Standard Doppler, MPI 90% 90%
Sun JP, J Heart Lung Transplant 2005 223
183
Standard Doppler echo ≥ 2 among PE, IVRT > 90 ms, E/A > 1.7 post
HT ≤ 6 months post
HT > 6 months
57%
60%
54%
93%
IVRT = isovolumic relaxation time, MPI = Myocardial performance index, PE = pericardial effusion, PHT = Mitral pressure half-time, SFFV = inferior 
vena caval systolic forward flow velocity.Cardiovascular Ultrasound 2008, 6:2 http://www.cardiovascularultrasound.com/content/6/1/2
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of new high-tech ultrasound technique and the use of
transthoracic CFR could produce some effect of improve-
ment in the ultrasound diagnostic accuracy of AAR in the
future time.
Cardiac allograft vasculopathy
The development of progressive CAD in HT has been rec-
ognised increasingly as long-term recipient survival has
improved. Because CAV remains the major cause of death
during long-term follow-up, its diagnosis is very impor-
tant. It is remained for years in the prevalent domain of
invasive techniques. Serial coronary angiography permits
the study of coronary arteries and also the visualisation of
coronary arteries by intravascular ultrasound (IVUS), that
represents the reference gold standard in this clinical set-
ting. Rapidly progressive vasculopathy by IVUS, defined
as an increase of ≥ 0.5 mm in intimal thickness within the
first year after HT, is a powerful predictor of all-cause mor-
tality, myocardial infarction and angiographic abnormal-
ities [47]. However, an annual angiographic evaluation is
difficult to perform and, with almost equal reliability
when compared with IVUS, CAV can be identified com-
bining information on donor age, 2-D echocardiographi-
cally determined wall motion score at rest and immuno-
fluorescence staining against anti-thrombin III in EMBs
late after HT [49]. In this view, coronary angiography
should be limited to patients with a high probability score
and not be used routinely for surveillance of CAV. Clinical
manifestations of CAV are often silent because the lack of
afferent sympathetic innervation of the transplanted
heart. Moreover, exercise performance in HT recipients
has a limited value since the donor heart is surgically den-
ervated without afferent parasympathetic or sympathetic
innervation. Abnormalities of the ventricular rate
response include resting tachycardia (due to parasympa-
thetic denervation), a slow heart rate during mild-moder-
ate exercise, a more rapid response during more strenuous
exercise, and a more prolonged time for the ventricular
rate to return to baseline during recovery. The heart rate
response during exercise and the diffuse nature of CAV
coronary abnormalities limit the sensitivity of ECG effort
tests to detect coronary artery vasculopathy. Pharmacolog-
ical stress echocardiography, a tool prognostically vali-
dated in groups of patients at risk for coronary artery
disease [50], is safe and well tolerated in HT recipients. A
varieties of stressors (adrenergic agents, vasodilators, cold
pressure test) are available but dobutamine is preferred
[51-58], mainly because denervation of the transplanted
heart increases the responsiveness to chronotropic stimu-
lation [59]. Dobutamine stress echocardiography (DSE)
identifies patients at risk for events and facilitates moni-
toring of CAV. A normal DSE predicts an uneventful clin-
ical course and justifies postponement of invasive studies
[53,54,56]. Its prognostic value is comparable to that of
IVUS and angiography [57]. DSE has been successfully
proposed in order to predict cardiac events in long-term
follow-up (4 years) of HT recipients [58]. The use of atro-
pine after dobutamine infusion is controversial since it is
evident that the heart of recipients is completely dener-
vated and there are conflicting evidence regarding para-
sympathetic re-innervation. However, it is recent the
demonstration that the adjunctive use of atropine in HT
patients during stress-echo aids in reaching 85% of maxi-
mum predicted heart rate [60]. Also dipyridamole stress
echocardiography is able to identify patients with altered
wall motion who need careful surveillance and probably
an invasive assessment [61,62]. Although wall motion at
rest and after dipyridamole administration and CAV are
predictors for cardiac events, only a wall motion score
index >1 after dipyridamole remains significant at multi-
variate analysis [63]. Adenosine has been used to evaluate
TTE-derived coronary flow reserve of left anterior descend-
ing artery (CFR) in transplant recipient, it showing 82%
sensitivity, 87% specificity and 85% accuracy for CAV
detection (cut-off point value ≤ 2.7) [64]. A shorter diasto-
lic flow velocity at rest (deceleration time of diastolic
velocity of ≤ 840 ms: sensitivity = 86%, specificity = 75%,
positive predictive value = 33%, negative predictive value
= 97%, p = 0.002) and a reduction of CFR (cut-off point
of CFR ≤ 2.6, sensitivity = 91%, specificity = 62%, positive
predictive value = 32%, negative predictive value = 97%,
p = 0.001) have demonstrated to be both reliable markers
for CAV-related major cardiac adverse events [65]. Figure
4 shows an abnormal CFR in a HT recipient. Of interest,
dipyridamole-derived CFR is related positively with Tissue
Doppler derived Sm velocity and negatively with E/Em
ratio in HT recipients: this findings indicates a possible
association of impaired coronary microcirculation with
both myocardial systolic dysfunction and increase of LV
filling pressures in this clinical setting [66].
Table 2 sumarises the main studies reporting sensitivity
and specificity of pharmacological stress in detecting CAV
and coronary artery stenosis > 50% in HT recipients (26).
In general, stress echocardiography appears as a very
important tool to identify CAV in HT recipients.
Echocardiography during endomyocardial byopsies
Another use of transthoracic echocardiography is the
monitorisation and the visualisation of the catheter dur-
ing the performance of endomyocardial biopsy [67]. The
use of the ecocardiography is important to avoid an use-
less and dangerous exposition to X-ray and permits to fol-
low adequately the movement of the catheter in the right
ventricle and to select the site for biopsy (Figure 5).
Echocardiography gives also the possibility to avoid dam-
aging of tricuspid valve, papillary muscles or chords and
to promptly identify the eventual presence of other com-
plications like pericardial effusion. Real time 3-D echocar-
diography seems very promising in improving the abilityCardiovascular Ultrasound 2008, 6:2 http://www.cardiovascularultrasound.com/content/6/1/2
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Reduced coronary flow reserve in a patient with coronary evidence of allograft vasculopathy Figure 4
Reduced coronary flow reserve in a patient with coronary evidence of allograft vasculopathy.
Use of 2-D echocardiography for monitoring the performance of endomyocardial biopsy in a HT recipient Figure 5
Use of 2-D echocardiography for monitoring the performance of endomyocardial biopsy in a HT recipient. The arrow indicates 
the site of the biopsy. Left panel: at the apex of right ventricle, right panel: al the level of the right side of the interventricular 
septum.Cardiovascular Ultrasound 2008, 6:2 http://www.cardiovascularultrasound.com/content/6/1/2
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to see the location of the bioptome during EMBs com-
pared with 2-D echocardiography and fluoroscopy
[68,69].
Heart donor storage
Heart donor storage is a main problem since patients in
HT waiting list have a 7.3% death rate and the average
waiting time is 2 to 3 years. In addition, there is a large
amount of ''marginal'' recipients, it being due to either
advanced age (> 65 years) or co-morbidity. Of conse-
quence, a gradual trend toward liberalizing donor selec-
tion criteria has been developed and an expansion of the
cardiac donor pool has involved accepting hearts of older
donors, tolerating longer organ ischemic times and
accepting hearts with structural and/or functional abnor-
malities, such as mild LV hypertrophy and mild valvular
abnormalities [70-72]. In this view, although it is fair to
recognize that transthoracic ultrasound imaging can be
suboptimal in several patients on ventilators, the role of
echocardiography has became crucial in order to detect
adequate LV function and lack of significant valvular heart
disease in the potential donors. Donors with echocardio-
graphic functional abnormalities at the time of donation
present an excellent 4 years survival rates [73]. The most
important problem for an adequate selection is, however,
the need of excluding donors with more than mild coro-
nary artery disease. Coronary angiography is recom-
mended for the majority of male donors older than 45
years and female donors older than 50 years, in order to
exclude significant coronary artery stenosis. A simpler
approach should be represented by bedside, pharmaco-
logical stress echocardiography, whose feasibility has
been recently validated in potential heart donors with
brain death: an aged donor with normal resting and stress
echo, without regional wall motion abnormalities or with
an hyperkinetic global response to the stress, can be
judged as a good candidate for an uneventful HT [74]. The
identification of hearts ''too good to die'' on the basis of
bedside resting and stress echo can be a critical way to
solve the mismatch between donor need and supply.
Comparison between pre-transplant donor stress-echo
and post-transplant recipient stress-echo could be per-
formed to assess normal or abnormal function of the
graft.
Conclusion
Transthoracic Doppler echocardiography is a primary
non-invasive modality for investigation of cardiac trans-
plant recipients. It is a versatile tool which provides com-
prehensive information about cardiac structure and
function. Echocardiographic examinations can be easily
performed at the bedside and serially repeated without
any patient's discomfort. Although sustained efforts to
develop and echocardiographic technique able to predict
the biopsy state have been performed, it has fair to recog-
nise that EMBs are still regarded as the gold standard for
detection of acute allograft rejection. Conversely, stress
echocardiography is able to identify accurately CAV and
has recognised prognostic value, which is comparable to
that of IVUS or angiography. A normal stress-echo justifies
Table 3: Main studies evaluating the accuracy of pharmacological stress echocardiography in detecting CAV and coronary artery 
stenosis > 50% in HT recipients (Mod from Thorn EM et al, Heart Fail Clin 2007)
Authors N. of pts Time post-HT
 (years)
Sensitivity 
for CV
Specificity 
for CAV
Sensitivity for 
cor. stenosis
Sensitivity for 
cor. stenosis
Dobutamine
Akosah KO, 1994 41 4.8 (0.25–10) 95% 50% 100% 41%
Herregods, J Heart Lung Tr1994 28 3.2 ± 1.3 50% 71% - -
Derumeaux G, JACC 1995 41 3.3 ± 1.7 86% 91% 100% 77%
Derumeaux G, Arch Mal Coeur 1996 64 3.3 ± 1.2 85% 97% 100% -
Akosah KO, JACC 1998 22 0.17 (0.04–0.3) 100% 73% 100% 59%
Derumeaux G, J Heart Lung Tr 1998 37 3.1 ± 1.7
4.7 ± 1.8
65%
92%
95%
73%
-
-
-
-
Spes GH, Circulation 1999 109 3.2 ± 3.1 72% 88% - -
Bacal F, J Heart Lung Tr 2004 38 > 4 - - 64% 91%
Dipyridamole
Ciliberto GR, Eur Heart J 1993 80 2.3 ± 0.5 80% 85% 100% 72%
Ciliberto GR. J Heart Lung Tr 2003 68 2.9 ± 1.9 80% 79% 100% 87%
Adenosine
Tona F J Heart Lung Tr 2006 73 8.0 ± 4.5 82% 87% - -
CFR = Coronary flow reserveCardiovascular Ultrasound 2008, 6:2 http://www.cardiovascularultrasound.com/content/6/1/2
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postponement of invasive studies. Bedside stress echocar-
diography is even useful to select appropriately heart
donors with brain death. Finally, echocardiographic mon-
itoring is simple and effective for monitoring a safe per-
formance of biopsy procedures.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SM conceived the study, participated in its design and
drafted the manuscript, MM and MG reviewed the manu-
script and participated in the design of the study, All the
authors read and approved the final manuscript.
References
1. Billingham ME, Cary NRB, Hammond EH, Kemnitz J, Marboe C,
McCallister HA, Snovar DC, Winters GL, Zerbe A: A working for-
mulation for the standardization of nomenclature in the
diagnosis of heart and lung rejection study group.  J Heart
Transplant 1990, 9:587-593.
2. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J,
Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris
AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reins-
moen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A,
Billingham ME: Revision of the 1990 working formulation for
the standardization of nomenclature in the diagnosis of
heart rejection.  J Heart Lung Transplant 2005, 24:1710-1720.
3. Hornick P, Rose M: Chronic rejection in the heart.  Methods Mol
Biol 2006, 333:131-144.
4. Kirlin JK: Heart Transplantation.  Churcill Livingstone edition;
2002. 
5. Peteiro J, Redondo F, Calviño R: Differences in heart transplant
physiology according to surgical technique.  J Thorac Cardiovasc
Surg 1996, 112:584-589.
6. El Gamel A, Yonan NA, Grant S: Orthotopic cardiac transplanta-
tion: a comparison of standard and bicaval Wythenshawe
techniques.  J Thorac Cardiovasc Surg 1995, 109:721-729.
7. Riberi A, Ambrosi P, Habib G, Kreitmann B, Yao JG, Gaudart J, Ghez
O, Metras D: Systemic embolism: a serious complication after
cardiac transplantation avoidable by bicaval technique.  Eur J
Cardiothorac Surg 2001, 19:307-311.
8. Kaye DM, Bergin P, Buckland M, Esmore D: Value of postoperative
assessment of cardiac allograft function by transesophageal
echocardiography.  J Heart Lung Transplant 1994, 13:165-172.
9. Bolad IA, Robinson DR, Webb C, Hamour I, Burke MM, Banner NR:
Impaired left ventricular systolic function early after heart
transplantation is associated with cardiac allograft vasculop-
athy.  Am J Transplant 2006, 6:161-168.
10. Wilhelmi M, Pethig K, Wilhelmi M, Nguyen H, Strüber M, Haverich A:
Heart transplantation: echocardiographic assessment of
morphology and function after more than 10 years of follow-
up.  Ann Thor Surg 2002, 74:1075-1079.
11. Dandel M, Hummel M, Müller J, Wellnhofer E, Meyer R, Solowjowa
N, Ewert R, Hetzer R: Reliability of tissue Doppler wall motion
monitoring after heart transplantation for replacement of
invasive routine screenings by optimally timed cardiac biop-
sies and catheterizations.  Circulation 2001, 104(12 Suppl
1):I184-I191.
12. Mena C, Wencker D, Krumholz HM, McNamara RL: Detection of
heart transplant rejection in adults by echocardiographic
diastolic indices: a systematic review of the literature.  J Am
Soc Echocardiogr 2006, 19:1295-300.
13. Pellicelli AM, Cosial JB, Ferranti E, Gomez A, Borgia MC: Alteration
of left ventricular filling evaluated by Doppler echocardiog-
raphy as a potential marker of acute rejection in orthotopic
heart transplant.  Angiology 1996, 47:35-41.
14. Aranda JM Jr, Weston MW, Puleo JA, Fontanet HL: Effect of loading
conditions on myocardial relaxation velocities determined
by Doppler tissue imaging in heart transplant recipients.  J
Heart Lung Transplant 1998, 17:693-697.
15. Puleo JA, Aranda JM, Weston MW, Cintrón G, French M, Clark L,
Fontanet HL: Noninvasive detection of allograft rejection in
heart transplant recipients by use of Doppler tissue imaging.
J Heart Lung Transplant 1998, 17:176-184.
16. Fyfe DA, Ketchum D, Lewis R, Sabatier J, Kanter K, Mahle W, Vincent
R: Tissue Doppler imaging detects severely abnormal myo-
cardial velocities that identify children with pre-terminal
cardiac graft failure after heart transplantation.  J Heart Lung
Transplant 2006, 25:510-517.
17. Stengel SM, Allemann Y, Zimmerli M, Lipp E, Kucher N, Mohacsi P,
Seiler C: Doppler tissue imaging for assessing left ventricular
diastolic dysfunction in heart transplant rejection.  Heart 2001,
86:432-437.
18. Sundereswaran L, Nagueh SF, Vardan S, Middleton KJ, Zoghbi WA,
Quiñones MA, Torre-Amione G: Estimation of left and right ven-
tricular filling pressures after heart transplantation by tissue
Doppler imaging.  Am J Cardiol 1998, 83:352-357.
19. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield
MM, Tajik AJ: Clinical utility of Doppler echocardiography and
tissue Doppler imaging in the estimation of left ventricular
filling pressures: A comparative simultaneous Doppler-cath-
eterization study.  Circulation 2000, 102:1788-1794.
20. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, Tajik AJ,
Seward JB: New index of combined systolic and diastolic myo-
cardial performance: a simple and reproducible measure of
cardiac function – a study in normals and dilated cardiomy-
opathy.  J Cardiol 1995, 26:357-366.
21. Mooradian SJ, Goldberg CS, Crowley DC, Ludomirsky A: Evalua-
tion of a noninvasive index of global ventricular function to
predict rejection after pediatric cardiac transplantation.  Am
J Cardiol 2000, 86:358-360.
22. Leonard GT, Fricker FJ, Pruett D, Harker K, Williams B, Schoweng-
erdt KO Jr: Increased myocardial performance index corre-
lates with biopsy-proven rejection in paediatric heart
transplant recipients.  J Heart Lung Transplant 2006, 25:61-66.
23. Vivekananthan K, Kalapura T, Mehra M, Lavie C, Milani R, Scott R,
Park M: Usefulness of the combined index of systolic and
diastolic myocardial performance to identify cardiac allo-
graft rejection.  Am J Cardiol 2002, 90:517-520.
24. Burgess MI, Bright-Thomas RJ, Yonan N, Ray SG: Can the index of
myocardial performance be used to detect acute cellular
rejection after heart transplantation?  Am J Cardiol 2003,
92:308-311.
25. Schwitter J, De Marco T, Globits S, Sakuma H, Klinski C, Chatterjee
K, Parmley WW, Higgins CB: Influence of felodipine on left ven-
tricular hypertrophy and systolic function in orthotopic
heart transplant recipients: possible interaction with
cyclosporine medication.  J Heart Lung Transplant 1999,
18:1033-1113.
26. Goodroe R, Bonnema DD, Lunsford S, Anderson P, Ryan-Baille B,
Uber W, Ikonomidis J, Crumbley AJ, VanBakel A, Zile MR, Pereira N:
Severe left ventricular hypertrophy 1 year after transplant
predicts mortality in cardiac transplant recipients.  J Heart
Lung Transplant 2007, 26:145-151.
27. Thorn EM, de Filippi CR: Echocardiography in the cardiac trans-
plant recipient.  Heart Failure Clin 2007, 3:51-67.
28. Nguyen V, Cantarovich M, Cecere R, Giannetti N: Tricuspid regur-
gitation after cardiac transplantation: how many biopsies are
too many?  J Heart Lung Transplant 2005, 24(7 Suppl):S227-S231.
29. Aziz TM, Burgess MI, Rahman AN, Campbell CS, Deiraniya AK, Yonan
NA: Risk factors for tricuspid valve regurgitation after ortho-
topic cardiac transplantation.  Ann Thorac Surg 1999,
68:1247-1251.
30. Bhatia SJ, Kirshenbaum JM, Shemin RJ, Cohn LH, Collins JJ, Di Sesa VJ,
Young PJ, Mudge GH Jr, Sutton MG: Time course of resolution of
pulmonary hypertension and right ventricular remodeling
after orthotopic cardiac transplantation.  Circulation 1987,
76:819-826.
31. Park MH, Scott RL, Uber PA, Harris BC, Chambers R, Mehra MR:
Usefulness of B-type natriuretic peptide levels in predicting
hemodynamic perturbations after heart transplantation
despite preserved left ventricular systolic function.  Am J Car-
diol 2002, 90:1326-1329.Cardiovascular Ultrasound 2008, 6:2 http://www.cardiovascularultrasound.com/content/6/1/2
Page 11 of 12
(page number not for citation purposes)
32. Fyfe DA, Mahle WT, Kanter KR, Wu G, Vincent RN, Ketchum DL:
Reduction of tricuspid annular Doppler tissue velocities in
pediatric heart transplant patients.  J Heart Lung Transplant 2003,
22:553-559.
33. Galderisi M, Severino S, Cicala S, Caso P: The usefulness of pulsed
tissue Doppler for the clinical assessment of right ventricular
function.  It Heart J 2002, 3(4):241-247.
34. Sun JP, Abdalla IA, Asher CR, Greenberg NL, Popoviæ ZB, Taylor
DO, Starling RC, Thomas JD, Garcia MJ: Non-invasive evaluation
of orthotopic heart transplant rejection by echocardiogra-
phy.  J Heart Lung Transplant 2005, 24:160-165.
35. Valantine HA, Hunt SA, Gibbons R, Billingham ME, Stinson EB, Popp
RL: Increasing pericardial effusion in cardiac transplant recip-
ients.  Circulation 1989, 79:603-609.
36. Al-Dadah AS, Guthrie TJ, Pasque MK, Moon MR, Ewald GA, Moazami
N: Clinical course and predictors of pericardial effusion fol-
lowing cardiac transplantation.  Transplant Proc 2007,
39:1589-1592.
37. Masuyama T, Valantine HA, Gibbons R, Schnittger I, Popp RL: Serial
measurement of integrated ultrasonic backscatter in human
cardiac allografts for the recognition of acute rejection.  Cir-
culation 1990, 81:829-839.
38. Angermann CE, Nassau K, Stempfle HU, Krüger TM, Drewello R,
Junge R, Uberfuhr P, Weiss M, Theisen K: Recognition of acute
cardiac allograft rejection from serial integrated backscatter
analyses in human orthotopic heart transplant recipients.
Comparison with conventional echocardiography.  Circulation
1997, 95:140-150.
39. Heimdal A, Steylen A, Torp H, Skiaerpe T: Real time strain rate
imaging of the left ventricle by ultrasound.  J Am Soc Echocardi-
ogr 1998, 11:1013-1019.
40. Eroglu E, Herbots L, Van Cleemput J, Droogne W, Claus P, D'hooge
J, Bijnens B, Vanhaecke J, Sutherland GR: Ultrasonic strain/strain
rate imaging – a new clinical tool to evaluate the trans-
planted heart.  Eur J Echocardiogr 2005, 6:186-195.
41. Marciniak A, Eroglu E, Marciniak M, Sirbu C, Herbots L, Droogne W,
Claus P, D'hooge J, Bijnens B, Vanhaecke J, Sutherland GR: The
potential clinical role of ultrasonic strain and strain rate
imaging in diagnosing acute rejection after heart transplan-
tation.  Eur J Echocardiogr 2007, 8:213-221.
42. Frigerio M, Pedrazzini G, Merli M, Vitali E: Heart Transplantation.
In Niguarda Cardiovascular Therapy Edited by: Savonitto S. Il Pensiero
Scientifico Editore, Roma; 2006:437-475. 
43. Desruennes M, Corcos T, Cabrol A, Gandjbakhch I, Pavie A, Léger P,
Eugène M, Bors V, Cabrol C: Doppler echocardiography for the
diagnosis of acute allograft rejection.  J Am Coll Cardiol 1988,
12:63-70.
44. Simmonds MB, Lythall DA, Slorach C, Ilsley CD, Mitchell AG, Yacoub
MH: Doppler examination of superior vena caval flow for the
detection of acute cardiac rejection.  Circulation 1992, 86(5
Suppl):II259-I266.
45. Morocutti G, Di Chiara A, Proclemer A, Fontanelli A, Bernardi G,
Morocutti A, Earle K, Albanese MC, Feruglio GA: Signal-averaged
echocardiography and Doppler echocardiographic study in
predicting acute rejection in heart transplantation.  J Heart
Lung Transplant 1995, 14(6 Pt 1):1065-1072.
46. Mouly-Bandini A, Vion-Dury J, Viout P, Mesana T, Cozzone PJ, Mon-
tiès JR: Value of Doppler echocardiography in the detection of
low-grade rejection after cardiac transplantation.  Transpl Int
1996, 9:131-136.
47. Picano E, De Pieri G, Salerno JA, Arbustini E, Distante A, Martinelli L,
Pucci A, Montemartini C, Viganò M, Donato L: Electrocardio-
graphic changes suggestive of myocardial ischemia elicited
by dipyridamole infusion in acute rejection early after heart
transplantation.  Circulation 1990, 81:72-77.
48. Nitenberg A, Tavolaro O, Benvenuti C, Loisance D, Foult JM, Hit-
tinger L, Castaigne A, Cachera JP, Vernant P: Recovery of a normal
coronary vascular reserve after rejection therapy in acute
human cardiac allograft rejection.  Circulation 1990,
81:1312-1318.
49. Tuzcu EM, Kapadia SR, Sachar R, Ziada KM, Crowe TD, Feng J, Mag-
yar WA, Hobbs RE, Starling RC, Young JB, McCarthy P, Nissen SE:
Intravascular ultrasound evidence of angiographically silent
progression in coronary atherosclerosis predicts long-term
morbidity and mortality after cardiac transplantation.  J Am
Coll Cardiol 2005, 45:1538-1542.
50. Störk S, Behr TM, Birk M, Uberfuhr P, Klauss V, Spes CH, Angermann
CE: Assessment of cardiac allograft vasculopathy late after
heart transplantation: when is coronary angiography neces-
sary?  J Heart Lung Transplant 2006, 25:1104-1008.
51. Sicari R, Ripoli A, Picano E, Di Giovanbattista R, Minardi G, Mat-
skeplishvili S, Ambatiello S, Pulignano G, Accarino M, Lusa AM, Del
Rosso GF, Pedrinelli R, Buziashvili Y: Perioperative prognostic
value of dipyridamole echocardiography in vascular surgery:
A large-scale multicenter study in 509 patients. EPIC (Echo
Persantine International Cooperative) Study Group.  Circula-
tion 1999, 100(19 Suppl):II269-II274.
52. Akosah KO, Mohanty PK, Funai JT, Jesse RL, Minisi AJ, Crandall CW,
Kirchberg D, Guerraty A, Salter D: Noninvasive detection of
transplant coronary artery disease by dobutamine stress
echocardiography.  J Heart Lung Transplant 1994, 13:1024-1038.
53. Herregods MC, Anastassiou I, Van Cleemput J, Bijnens B, De Geest
H, Daenen W, Vanhaecke J: Dobutamine stress echocardiogra-
phy after heart transplantation.  J Heart Lung Transplant 1994,
13:1039-1044.
54. Derumeaux G, Redonnet M, Mouton-Schleifer D, Bessou JP, Cribier
A ,  S a o u d i  N ,  K o n i n g  R ,  S o y e r  R ,  L e t a c  B :  Dobutamine stress
echocardiography in orthotopic heart transplant recipients.
VACOMED Research Group.  J Am Coll Cardiol 1995,
25:1665-1672.
55. Derumeaux G, Redonnet M, Mouton-Schleifer D, Cribier A, Soyer R,
Letac B: Value of dobutamine echocardiography in the detec-
tion of coronary disease in heart transplant patient. Groupe
de Recherche VACOMED.  Arch Mal Coeur Vaiss 1996,
89:687-694.
56. Akosah KO, McDaniel S, Hanrahan JS, Mohanty PK: Dobutamine
stress echocardiography early after heart transplantation
predicts development of allograft coronary artery disease
and outcome.  J Am Coll Cardiol 1998, 31:1607-1614.
57. Derumeaux G, Redonnet M, Soyer R, Cribier A, Letac B: Assess-
ment of the progression of cardiac allograft vasculopathy by
dobutamine stress echocardiography.  J Heart Lung Transplant
1998, 17:259-267.
58. Spes CH, Klauss V, Mudra H, Schnaack SD, Tammen AR, Rieber J, Sie-
bert U, Henneke KH, Uberfuhr P, Reichart B, Theisen K, Angermann
CE:  Diagnostic and prognostic value of serial dobutamine
stress echocardiography for noninvasive assessment of car-
diac allograft vasculopathy: a comparison with coronary ang-
iography and intravascular ultrasound.  Circulation 1999,
100:509-515.
59. Bacal F, Moreira L, Souza G, Rodrigues AC, Fiorelli A, Stolf N, Bocchi
E, Bellotti G, Ramires JA: Dobutamine stress echocardiography
predicts cardiac events or death in asymptomatic patients
long-term after heart transplantation: 4-year prospective
evaluation.  J Heart Lung Transplant 2004, 23:1238-1244.
60. Borow KM, Neumann A, Arensman FW, Yacoub MH: Cardiac and
peripheral vascular responses to adrenoceptor stimulation
and blockade after cardiac transplantation.  J Am Coll Cardiol
1989, 14:1229-1238.
61. Kociolek LK, Bierig SM, Herrmann SC, Labovitz AJ: Efficacy of atro-
pine as a chronotropic agent in heart transplant patients
undergoing dobutamine stress echocardiography.  Echocardi-
ography 2006, 23:383-387.
62. Ciliberto GR, Massa D, Mangiavacchi M, Danzi GB, Pirelli S, Faletra F,
Frigerio M, Gronda E, De Vita C: High-dose dipyridamole
echocardiography test in coronary artery disease after heart
transplantation.  Eur Heart J 1993, 14:48-52.
63. Ciliberto GR, Parodi O, Cataldo G, Mangiavacchi M, Alberti A, Paro-
lini M, Frigerio M: Prognostic value of contractile response dur-
ing high-dose dipyridamole echocardiography test in heart
transplant recipients.  J Heart Lung Transplant 2003, 22:526-532.
64. Tona F, Caforio AL, Montisci R, Angelini A, Ruscazio M, Gambino A,
Ramondo A, Thiene G, Gerosa G, Iliceto S: Coronary flow reserve
by contrast-enhanced echocardiography: a new noninvasive
diagnostic tool for cardiac allograft vasculopathy.  Am J Trans-
plant 2006, 6:998-1003.
65. Tona F, Caforio AL, Montisci R, Gambino A, Angelini A, Ruscazio M,
Toscano G, Feltrin G, Ramondo A, Gerosa G, Iliceto S: Coronary
flow velocity pattern and coronary flow reserve by contrast-
enhanced transthoracic echocardiography predict long-
term outcome in heart transplantation.  Circulation 2006, 114(1
Suppl):I49-I55.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cardiovascular Ultrasound 2008, 6:2 http://www.cardiovascularultrasound.com/content/6/1/2
Page 12 of 12
(page number not for citation purposes)
66. Giacomin E, Gasperini S, Zacà V, Ballo P, Diciolla F, Bernazzali S, Mac-
cherini M, Chiavarelli M, Galderisi M, Mondillo S: Relationship of
coronary microcirculatory dysfunction and left ventricular
longitudinal function in heart transplant recipients.  J Heart
Lung Transplant 2008 in press.
67. Mortensen SA, Egeblad H: Endomyocardial biopsy guided by
cross-sectional echocardiography.  Br Heart J 1983, 50:246-251.
68. Aggarwal M, Drachenberg C, Douglass L, de Filippi C: The efficacy
of real-time 3-dimensional echocardiography for right ven-
tricular biopsy.  J Am Coll Cardiol 2005, 18:1208-1212.
69. Amitai ME, Schnittger I, Popp RL, Chow J, Brown P, Liang DH: Com-
parison of three-dimensional echocardiography to two-
dimensional echocardiography and fluoroscopy for monitor-
ing of endomyocardial biopsy.  Am J Cardiol 2007, 99:864-866.
70. Marelli D, Laks H, Fazio D, Moore S, Moriguchi J, Kobashigawa J: The
use of donor hearts with left ventricular hypertrophy.  J Heart
Lung Transplant 2000, 19:496-50.
71. Brock MV, Salazar JD, Cameron DE, Baumgartner WA, Conte JV:
The changing profile of the cardiac donor.  J Heart Lung Trans-
plant 2001, 20:1005-1009.
72. Zaroff JG, Rosengard BR, Armstrong WF, Babcock WD, D'Alessan-
dro A, Dec GW, Edwards NM, Higgins RS, Jeevanandum V, Kauffman
M, Kirklin JK, Large SR, Marelli D, Peterson TS, Ring WS, Robbins RC,
Russell SD, Taylor DO, Van Bakel A, Wallwork J, Young JB: Consen-
sus conference report: maximizing use of organs recovered
from the cadaver donor: cardiac recommendations, March
28–29, 2001, Crystal City, Va.  Circulation 2002, 106:836-841.
73. Sopko N, Shea KJ, Ludrosky K, Smedira N, Hoercher K, Taylor DD,
Starling RR, Gonzalez-Stawinski GV: Survival is not compromised
in donor hearts with echocardiographic abnormalities.  J Surg
Res 2007, 143:141-144.
74. Arpesella G, Gherardi S, Bombardini T, Picano E: Recruitment of
aged donor heart with pharmacological stress echo. A case
report.  Cardiovasc Ultrasound 4:3. 2006 Jan 24;